• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British journal of ophthalmology >Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography
【24h】

Long-term results of intravitreal ranibizumab for the treatment of retinal angiomatous proliferation and utility of an advanced RPE analysis performed using spectral-domain optical coherence tomography

机译：玻璃体内雷珠单抗治疗视网膜血管瘤增生的长期结果以及使用光谱域光学相干断层扫描技术进行的高级RPE分析的实用性

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: To report the results of 3-year follow-up examinations after intravitreal ranibizumab (IVR) injection for the treatment of retinal angiomatous proliferation (RAP) and to examine the utility of an advanced retinal pigment epithelium (RPE) analysis performed using spectral-domain optical coherence tomography (SD-OCT). Methods: We retrospectively reviewed 17 treatment-na?ve eyes in 14 patients (4 men, 10 women; age range 71-87 years; mean age 80 years) treated with IVR. All the patients received three consecutive monthly injections of 0.5 mg/0.05 mL of ranibizumab as an induction treatment. Retreatment was allowed if evidence of clinical deterioration was noted or if an SD-OCT examination performed at a 1-month follow-up showed intraretinal oedema, subretinal fluid, or recurrent pigment epithelial detachment. The primary outcome measures were best-corrected visual acuity (BCVA) and central foveal thickness (CFT) as evaluated using SD-OCT. Furthermore, we investigated the atrophic area at 36 months using advanced RPE analysis provided by SD-OCT and analysed the correlation with the BCVA. Results: The mean BCVA was well maintained from 0.57 at baseline to 0.52 at 36 months (p=0.219). The CFT decreased signi ficantly from 317 to 223 μm at 36 months (p<0.001). The mean number of injections was 10.2. Sixteen of the 17 patients (94.1%) showed recurrence during the maintenance phase. Better visual acuity at 36 months was also associated with better visual acuity at baseline and absence of macular atrophy (MA) identified with advanced RPE analysis at 36 months ( p<0.001, p=0.012, respectively). Conclusions: The intravitreal injection of ranibizumab was effective for stabilising vision in patients with RAP, as evaluated at a 3-year follow-up examination. Advanced RPE analysis is useful for investigating atrophic areas after IVR. Visual acuity at baseline and progression of MA might be important for BCVA after IVR.
机译：目的：报告玻璃体内雷珠单抗（IVR）注射后治疗视网膜血管瘤增生（RAP）后三年随访检查的结果，并检查使用光谱仪进行的高级视网膜色素上皮（RPE）分析的实用性域光学相干断层扫描（SD-OCT）。方法：我们回顾性分析了接受IVR治疗的14例患者（4例男性，10例女性;年龄范围71-87岁;平均年龄80岁）的17例初次治疗的眼睛。所有患者均接受连续三个月的雷珠单抗0.5 mg / 0.05 mL注射作为诱导治疗。如果发现临床恶化迹象或在1个月的随访中进行SD-OCT检查显示视网膜内水肿，视网膜下积液或色素上皮反复脱离，则允许进行再次治疗。主要结局指标为使用SD-OCT评估的最佳矫正视力（BCVA）和中央凹中央厚度（CFT）。此外，我们使用SD-OCT提供的高级RPE分析调查了36个月时的萎缩区域，并分析了与BCVA的相关性。结果：平均BCVA保持良好，从基线的0.57到36个月的0.52（p = 0.219）。在36个月时，CFT从317μm显着下降（p <0.001）。平均注射次数为10.2。 17例患者中有16例（94.1％）在维持阶段出现复发。在36个月时更好的视力还与基线时更好的视力以及在36个月时通过高级RPE分析确定的无黄斑萎缩（MA）相关（分别为p <0.001，p = 0.012）。结论：根据3年的随访检查，玻璃体内注射兰尼单抗可以有效稳定RAP患者的视力。先进的RPE分析对于调查IVR后的萎缩区域非常有用。 IVR后，BCVA的基线和MA进程的视敏度可能对BCVA很重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号